Page last updated: 2024-11-06

quindoxin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Quindoxin is a synthetic quinoline-based antimicrobial drug with broad-spectrum activity against both Gram-positive and Gram-negative bacteria. Its synthesis involves a multi-step process starting from quinoline. It is primarily used in veterinary medicine for the treatment of bacterial infections in poultry and swine. Quindoxin inhibits bacterial DNA synthesis by interfering with the enzyme DNA gyrase. This inhibition leads to bacterial cell death. Quindoxin is studied due to its effectiveness against various bacterial pathogens, its unique mechanism of action, and its potential for use in human medicine. However, its use in food animals has raised concerns about potential residues in meat and eggs, leading to regulatory restrictions in some countries.'

quindoxin: RN given refers to parent cpd; structure in Negwer, 5th ed, #702 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72073
CHEMBL ID2104626
CHEBI ID179448
SCHEMBL ID1323909
MeSH IDM0044298

Synonyms (48)

Synonym
quinoxaline-di-n-oxide
CHEBI:179448
4-oxidoquinoxalin-1-ium 1-oxide
celbar
bay-va 9391
nsc-193508
ici 8173
quinoxaline 1,4-di-n-oxide
quindoxin
quinoxaline,4-dioxide
quinoxaline 1,4-dioxide
quinoxaline di-n-oxide
bayo n-ox
quinoxaline dioxide
usaf h-1
nsc193508
wln: t66 bn enj bo eo
2423-66-7
grofas
nsc-21653
nsc21653
inchi=1/c8h6n2o2/c11-9-5-6-10(12)8-4-2-1-3-7(8)9/h1-6
NCGC00160461-01
AKOS006274508
dtxcid6026165
tox21_111830
cas-2423-66-7
dtxsid8046165 ,
CKIHZSGJPSDCNC-UHFFFAOYSA-N
quinoxaline-1,4-dioxide
SCHEMBL1323909
ici-8173
CHEMBL2104626
amx8j6ys1h ,
quindoxin [inn]
1lambda,4lambda-quinoxaline-1,4-dione
SR-01000945211-1
sr-01000945211
SR-01000945211-2
quinoxaline-1,4-diium-1,4-bis(olate)
Q27274014
1-oxo-1,4-dihydro-1|e?-quinoxalin-1-ylium-4-olate
CAA42366
Q0110
mfcd00869077
EN300-154722
E84447
Z1198155535

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The acute toxicity of six quinoxaline 1,4-di-N-oxides has been evaluated in an attempt to determine: a) the feasibility of testing systemic toxicity of these compounds in a very preliminary phase without an adequate formulation for in vivo administration, b) the LD50 range and the toxic target organ of these compounds in order to have an approximation of the structure-activity relationship."( Comparative acute systemic toxicity of several quinoxaline 1,4-di-N-oxides in Wistar rats.
Azqueta, A; Cia, F; de Cerain, AL; García-Jalón, JA; García-Rodríguez, A; Gil, AG; Monge, A; Zarranz, B, 2007
)
0.34
" The relatively new QdNOs, cyadox (CYA), mequindox (MEQ), quinocetone (QCT) and their metabolites, were selected for elucidation of their toxic mechanisms in H295R cells."( High risk of adrenal toxicity of N1-desoxy quinoxaline 1,4-dioxide derivatives and the protection of oligomeric proanthocyanidins (OPC) in the inhibition of the expression of aldosterone synthetase in H295R cells.
Chen, D; Cheng, G; Dai, M; Guo, P; Ihsan, A; Liu, Z; Luo, X; Wang, X; Yang, C; Yuan, Z, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
"As an effort to develop novel selective hypoxia-cytotoxins and to improve bioavailability and pharmacological and toxicological properties of quinoxaline N1,N4-dioxide derivatives (L1 = 3-amino-6(7)-chloroquinoxaline-2-carbonitrile N1,N4-dioxide, L2 = 3-amino-6(7)-bromoquinoxaline-2-carbonitrile N1,N4-dioxide and L3 = 3-amino-6(7)-methylquinoxaline-2-carbonitrile N1,N4-dioxide) and to get a synergism among metals and these type of bioreductive agents, L2 and three novel Cu(II) complexes of general formulae [Cu(II)(H2O)x(L - H)2], where L = L1 (x = 1), L2 (x = 0) or L3 (x = 2) were developed."( Novel Cu(II) quinoxaline N1,N4-dioxide complexes as selective hypoxic cytotoxins.
Abram, U; Araujo, J; Azqueta, A; Cerecetto, H; Costa-Filho, AJ; Gambino, D; González, M; Lavaggi, ML; López de Cerain, A; Torre, MH; Vega, AM, 2005
)
0.33
" tuberculosis resistant to currently used antitubercular drugs including multidrug-resistant strains (MDR-TB resistant to isoniazid and rifampicin); (ii) activity against non-replicating persistent (NRP) bacteria; (iii) MBC; (iv) maximum tolerated dose, oral bioavailability and in vivo efficacy in mice; and (v) potential for cross-resistance with another bioreduced drug, PA-824."( In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide.
Aldana, I; Cho, SH; Franzblau, SG; Goldman, RC; Lenaerts, AJ; Maddry, JA; Monge, A; Pérez-Silanes, S; Solano, B; Vicente, E; Villar, R, 2008
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The effect of cyadox was very low even at the highest dosage tested."( Cytogenetic effects of quinoxaline-1,4-dioxide-type growth-promoting agents. I. Micronucleus test in rats.
Cihák, R; Srb, V, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinoxaline derivativeAny naphthyridine derivative that is a derivative of quinoxaline (1,4-naphthyridine).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen nuclear receptor alphaHomo sapiens (human)Potency6.00120.000229.305416,493.5996AID743075
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (64)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (21.88)18.7374
1990's2 (3.13)18.2507
2000's18 (28.13)29.6817
2010's25 (39.06)24.3611
2020's5 (7.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.26 (24.57)
Research Supply Index4.20 (2.92)
Research Growth Index5.47 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (7.58%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other61 (92.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]